Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

Andrew Leonard Laccetti, Matthew T. Campbell, Landon C. Brown et al.|Cancer Medicine|2021

Cited by 19